νΈλΌλ₯μΌμ°
νΈλΌλ₯μΌμ°μ ν©μ± λΌμ΄μ μ μ¬μ²΄λ‘, μΆνμ μ‘°μ νκΈ° μν **νμ¬μ μμ©ν΄μ **λ‘ μ¬μ©λ©λλ€. **κ³ μ¬μ μμ©ν΄ μν** λ° νΉμ ννμ **μκ³ μ₯μ **κ° μλ νμμκ² νΉν μ μ΅ν©λλ€. **μμ ν:** μμνμμλ μΈμ, μμ μ μΆν(μ: κ·Έλ μ΄νμ΄λ μμ ), *μ£Όνμ μΆ©*(νμΆ©) λλ λ©΄μ λ§€κ°μ± νμν κ°μμ¦(IMTP)κ³Ό κ΄λ ¨λ μΆνμ νν μ¬μ©λ©λλ€. > **κ²½κ³ :** μ κΈ°λ₯ μ₯μ λλ κΈ°μ‘΄μ νμ μμ μ± μ§νμ΄ μλ νμμκ²λ μ£Όμν΄μ μ¬μ©ν΄μΌ ν©λλ€.
μμ© κΈ°μ : Tranexamic acid is a synthetic lysine analogue that reversibly binds to the **lysine binding sites of plasminogen**. Plasminogen β (blocked by TXA) β Plasmin This prevents the action of plasmin on fibrin, thereby delaying **fibrin dissolution** (fibrinolysis) and reducing bleeding. By stabilizing the clot, it helps maintain hemostasis in bleeding disorders.
ν¬μ¬ κ²½λ‘
κΈκΈ°
- Disseminated intravascular coagulation (DIC)
- Thromboembolic disease
- Severe renal impairment (without dose adjustment)
μ΄μλ°μ
- Gastrointestinal upset (vomiting, diarrhea)
- Hypotension (if given rapidly IV)
- Seizures (at high doses)
- Retinal changes (rare, high doses)
μ½λ¬Ό μνΈμμ©
- Estrogens Β· Increased risk of thrombosis Β· moderate
- Tissue plasminogen activators (e.g., alteplase) Β· Antagonizes fibrinolytic effects Β· major
λͺ¨λν°λ§
- Clinical signs of bleeding
- Coagulation profiles (PT, aPTT, TEG/ROTEM)
- Renal function
κ³Όμ©λ
Overdosage may result in severe **gastrointestinal signs** (vomiting, diarrhea), **hypotension**, and neurological signs including **seizures** (due to GABA-A receptor antagonism). Treatment is symptomatic and supportive.
VetSheet μ½λ¬Ό λ νΌλ°μ€λ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μμ¬κ²°μ 보쑰 λꡬμ΄λ©°, μ λ¬Έμ νλ¨μ΄λ μ μ‘°μ¬μ μ΅μ λΌλ²¨μ λμ νμ§ μμ΅λλ€.